Stopping the Nonsense

Herper, Matthew
October 2007
Forbes Asia;10/1/2007, Vol. 3 Issue 16, p62
The article discusses the treatment of a rare genetic flaw called nonsense misspelling. Matthew Deriggi is among the 13,000 boys in the U.S. who have a rare form of muscular dystrophy known as Duchenne. An unknown New Jersey biotech called PTC Therapeutics, made an experimental drug that has helped Matt after only one month of treatment. By targeting nonsense mutations in general, the PTC drug might help legions of patients across an expanding array of rare genetic ailments.


Related Articles

  • BOX 7-3 MUSCULAR DYSTROPHY. Scanlon, Valerie C.; Sanders, Tina // Essentials of Anatomy & Physiology;Jan2007, p148 

    Information on muscular dystrophy from Chapter 7 of the book "Essentials of Anatomy & Physiology" is presented. It refers to a group of genetic diseases in which muscle tissue is replaced by fibrous connective tissue or by fat. Duchenne's muscle dystrophy is the most common form. It is a...

  • Lived Experience of Mothers with Duchenne Muscular Dystrophy Children, Kathmandu. Prasai, S.; Uprety, S. // Journal of Institute of Medicine;Aug2015, Vol. 37 Issue 2, p85 

    Introduction: Duchenne Muscular Dystrophy (DMD) is a genetic neuromuscular disorder with functional disability. In Nepal, eight hundred cases have been registered in Muscular Dystrophy Foundation (MDF). The Survival age of child with Duchene Muscular Dystrophy (DMD) is not more than twenty four...

  • Spoken presentations.  // Journal of Medical Genetics;Sep2002 Supplement, Vol. 39, pS27 

    Discusses the abstract of the research paper entitled 'Duchenne muscular dystrophy--past, present and future,' by Kay E. Davies and presented during the British Human Genetics Conference at the University of York in England in September 2002.

  • Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Falzarano, Maria Sofia; Scotton, Chiara; Passarelli, Chiara; Ferlini, Alessandra // Molecules;2015, Vol. 20 Issue 10, p18168 

    Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle. The...

  • Immunadsorption therapy for end stage heart failure due to Duchenne muscular dystrophy. Buchhorn, Reiner; Willaschek, Christian; Selbach, Jochen; Jahns, Roland // Open Journal of Pediatrics;Mar2013, Vol. 3 Issue 1, p17 

    We report about a successful immunadsorption therapy of a boy with end stage heart failure due to Duchenne muscular dystrophy who has little chance to get cardiac transplantation. Prior to this therapy a medical therapy with an angiotensin converting enzyme inhibitor, a low dose betablocker, an...

  • Can the caudal extent of fusion in the surgical treatment of scoliosis in Duchenne muscular dystrophy be stopped at lumbar 5? Takaso, Masashi; Nakazawa, Toshiyuki; Imura, Takayuki; Ueno, Masaki; Saito, Wataru; Shintani, Ryousuke; Takahashi, Kazuhisa; Yamazaki, Masashi; Ohtori, Seiji; Okamoto, Makihito; Masaki, Takashi; Okamoto, Hirotsugu; Okutomi, Toshiyuki; Ishii, Kazuhiro; Ueda, Yasuhiro // European Spine Journal;May2010, Vol. 19 Issue 5, p787 

    Instrumentation and fusion to the sacrum/pelvis has been a mainstay in the surgical treatment of scoliosis in Duchenne muscular dystrophy (DMD) and is recommended to correct pelvic obliquity. The caudal extent of instrumentation and fusion in the surgical treatment of scoliosis in DMD has...

  • Duchenne Muscular Dystrophy: Canadian Paediatric Neuromuscular Physicians Survey. McMillan, Hugh J.; Campbell, Craig; Mah, Jean K. // Canadian Journal of Neurological Sciences;Mar2010, Vol. 37 Issue 2, p195 

    Background: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. Method: To assess the current care of paediatric DMD patients in Canada, a questionnaire was mailed to 17 physicians who were members of the Canadian paediatric neuromuscular group. Areas of...

  • Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Nakamura, Harumasa; Kimura, En; Mori-Yoshimura, Madoka; Komaki, Hirofumi; Matsuda, Yu; Goto, Kanako; Hayashi, Yukiko K.; Nishino, Ichizo; Takeda, Shin'ichi; Kawai, Mitsuru // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, Special section p1 

    Background: Currently, clinical trials for new therapeutic strategies are being planned for Duchenne and Becker muscular dystrophies (DMD/BMD). However, it is difficult to obtain adequate numbers of patients in clinical trials. As solutions to these problems, patient registries are an important...

  • Duchenne's Legacy. Sorbie, Charles // Orthopedics;Jan2004, Vol. 27 Issue 1, p13 

    Discusses research on Duchenne's muscular dystrophy. Reference to a study by Byrne et al., published in a 2003 issue of the "Medical Journal of Australia"; Study methods; Results.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics